Document is current
Any future updates will be listed below
-
Authors
Dagenais, Gilles R. http://orcid.org/0000-0002-4509-2004
Rydén, Lars
Leiter, Lawrence A.
Lakshmanan, Mark
Dyal, Leanne
Probstfield, Jeffrey L.
Atisso, Charles Messan
Shaw, Jonathan E.
Conget, Ignacio
Cushman, William C.
Lopez-Jaramillo, Patricio
Lanas, Fernando
Munoz, Ernesto German Cordona
Pirags, Valdis
Pogosova, Nana
Basile, Jan
Sheu, Wayne H. H.
Temelkova-Kurktschiev, Theodora
Raubenheimer, Peter J.
Keltai, Matyas
Hall, Stephanie
Pais, Prem
Colhoun, Helen M.
Riddle, Matthew C.
Gerstein, Hertzel C.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01394952 at ClinicalTrials.govDocuments that mention this clinical trial
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
https://doi.org/10.1186/s12933-021-01386-4
New drugs in preclinical and early stage clinical development in the treatment of heart failure
https://doi.org/10.1080/13543784.2019.1551357
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
https://doi.org/10.2337/ds16-0026
Nonglycemic Outcomes of Antidiabetic Medications
https://doi.org/10.2337/cd18-0015
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
https://doi.org/10.1016/j.ahj.2015.02.002
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
https://doi.org/10.1186/s12933-020-01179-1
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
https://doi.org/10.1016/j.ahj.2015.12.009
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes
https://doi.org/10.1186/s12933-022-01594-6
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 30 September 2020
Accepted: 15 November 2020
First Online: 25 November 2020
Ethics approval and consent to participate
: Ethics review boards responsible for each of the 371 participating sites (24 countries) approved the protocol and each of the 9901 participants provided written informed consent.
: Not applicable.
: GRD received honoraria from BAYER for lectures. LR received research grants from Swedish Heart–Lung Foundation, Stockholm County council, Family Erling Perssons Foundation and Boehringer-Ingelheim and speaker honoraria from Bayer AG, Boehringer-Ingelheim, Eli Lilly and Novo Nordisk. LAL received research grants from, provided CME on behalf of and/or acted as an adviser to AstraZeneca, Boehringer Ingelheim, Eli Lilly, GSK, Janssen, Lexicon, Merck, Novo Nordisk, Sanofi, and Servier. ML is employed by Eli Lilly. LD has no competing interests. JLP has no competing interests. CMA is employed by Eli Lilly. JES has received honoraria from AstraZeneca, Merck Sharp & Dohme Corp., Mylan, Sanofi. Eli Lilly, Novo Nordisk and Boehringer Ingelheim. IC has received honoraria for lectures and consulting fees from Abbot, Medtronic, Bayer, GlaxoSmithKline, Eli Lilly, Novo Nordisk, Sanofi-Aventis, Novartis and MSD. WCCPLJ has received honoraria for speaking from Merck, Menarini, Sanofi, Abbott, WCC has received institutional grant support from Eli Lilly. FL has no competing interests. EGCM acted as an adviser for Servier and received honoraria from Menarini, Sanofi, MSD, Silanes, Novo, Stendhal, Boryun for lectures. VP has no competing interests. NP has no competing interests. JB received research grants from Eli Lilly, ReCor, and Ablative Solutions. He is a consultant for both Medtronic and Up-to-Date. WHHS provided CME and/or acted as an adviser to MSD, AstraZeneca, Boehringer Ingelheim, Tanabe, Takeda, Eli Lilly, Bayer’s, Novo Nordisk, and Sanofi. TTK has no competing interests. PJR has no competing interests. MK has no competing interests. SH has no competing interests. PP has no competing interest. HMC has received grants from Eli Lilly, AstraZeneca, Regeneron, Pfizer, Novo Nordisk, honoraria for speaker bureau from Eli Lilly and advisory panel from Sanofi Aventis and Novartis, and is shareholder Roche Pharma. MCR reports grant support through Oregon Health & Science University from Astra Zeneca, Eli Lilly, and Novo Nordisk, and honoraria for consulting from Adocia, AstraZeneca, Eli Lilly, GlaxoSmithKline, Intercept, Novo Nordisk, Sanofi, and Theracos. HCG holds the McMaster-Sanofi Population Health Institute Chair in Diabetes Research and Care. He reports research grants from Eli Lilly, AstraZeneca, Merck, Novo Nordisk and Sanofi; honoraria for speaking from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi; and consulting fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, Janssen, Sanofi, and Kowa.
